Replies to post #3220 on Nexien BioPharma Inc (NXEN)

[scoobey-do]

The amended 8-k is being reported by a company: Kanativa Inc. (f/k/a Intiva Inc.) and the number of shares reported is 19,000,000 or 35.37% of the 53,715,996 shares outstanding.

This percentage is calculated based on 53,715,996 shares of common stock, par value of $0.0001 per share, of the Issuer (defined below) outstanding as of March 1, 2019, as reported on the Issuer’s Schedule 14C, filed with the SEC on March 8, 2019.

I see it as an amendment to the original report reported earlier.

What I like is the fact the a company owns 35% of Nexien Biopharma, Inc.